Abstract
Sepsis, defined as life-threatening organ dysfunction, is one of the most common causes of mortality in intensive care units with limited therapeutic options. However, the mechanism underlying the regulation of epigenetics on sepsis remains largely undefined. Here we showed that JMJD3, the histone lysine demethylase, played a critical role in the epigenetic regulation of innate immunity during early sepsis. Pharmacological inhibition of JMJD3 by GSKJ4 protected mice against early septic death and reduced pro-inflammatory cytokine interleukin-1β (IL-1β) production as well as IL-6, tumor necrosis factor-α (TNF-α), and monocyte chemotactic protein-1 (MCP-1) expression. Interestingly, GSKJ4 up-regulated the transcription of anti-inflammatory microRNA-146a (miR-146a) in peritoneal macrophages from septic mice. Mechanistically, JMJD3 negatively regulated the transcription of miR-146a via its demethylation of H3K27me3 on the promoter of miR-146a. Moreover, the transcription of miR-146a was positively regulated by nuclear factor-κB (NF-κB) p65. Inhibition of NF-κB p65 promoted JMJD3 binding to miR-146a promoter and decreased the tri-methylation level of H3K27, while the inhibition of JMJD3 did not affect the recruitment of NF-κB p65 to miR-146a promoter. These results highlight an epigenetic mechanism by which JMJD3 was inhibited by NF-κB p65 from binding to miR-146a promoter to promote the anti-inflammatory response. Taken together, our findings uncover a key role for JMJD3 in modulating the miR-146a transcription and shed light on the JMJD3 inhibitors could be potential therapeutic agents for early sepsis therapy.
Highlights
Sepsis is a heterogeneous syndrome that usually characterized as life-threatening organ dysfunction caused by infection [1]
We found that GSKJ4 treatment protected sepsis against inflammation
The clinical Escherichia coli (E. colia for short) strains were isolated from human clinical specimens and injected intraperitoneally at the concentration of 5 × 107 CFU per mouse
Summary
Sepsis is a heterogeneous syndrome that usually characterized as life-threatening organ dysfunction caused by infection [1]. Host innate immune system is strongly activated by pathogen-associated molecular patterns (PAMPs) to release interleukin-1β (IL-1β) and other pro-inflammatory cytokines. The cytokine storm can exacerbate inflammatory responses in the host, which leads to multiple organ failure and even early septic mortality [2, 3]. Targeted inhibition of key inflammatory regulators that control dysregulated immune response could be a useful strategy for early sepsis therapy. The endotoxin lipopolysaccharide (LPS) can epigenetically control the inflammatory response, which contributes to the morbidity and mortality of gram-negative sepsis. JMJD3 contributes to the production of pro-inflammatory IL-1β [7]. Inhibition of JMJD3 by GSKJ4, a small-molecule inhibitor of JMJD3, decreases the expression of inflammatory mediators IL-1β, IL-6, tumor necrosis factor-α (TNF-α), etc. The therapeutic effect of GSKJ4 on sepsis is unknown
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.